[Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
Ohtake
Akiyoshi
A
akiyoshi.ohtake@jp.astellas.com
Sato
Shuichi
S
Ikeda
Ken
K
Sasamata
Masao
M
Miyata
Keiji
K
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D018727:Muscarinic Antagonists / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D009130:Muscle, Smooth / Q000187:drug effects; D011812:Quinuclidines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D011976:Receptors, Muscarinic / Q000378:metabolism; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000187:drug effects; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D011976:Receptors, Muscarinic; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate